Amunix Congratulates Versartis on Its Positive Phase 2a

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Amunix Congratulates Versartis on Its Positive Phase 2a Results With VRS-317

MOUNTAIN VIEW, CA--(Marketwired - Jun 30, 2014) - Amunix Operating Inc., a biotechnology company developing a half-life extension technology for peptides, proteins and small molecules, congratulates Versartis, Inc. ( NASDAQ : VSAR ) on its positive clinical data with VRS-317, a novel, long-acting form of recombinant human growth hormone (rhGH). Positive Phase 2a data from the Versartis six month clinical trial demonstrating the safety and efficacy of VRS-317 in the treatment of children with growth hormone deficiency (GHD) were recently presented at the ICE/ENDO conference. VRS-317, which is a new chemical entity, combines the same human growth hormone amino acid sequence utilized in currently approved human growth hormone products with Amunix's protein-based XTEN half-life extension technology. VRS-317 was designed to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance and therefore treatment outcomes. The proprietary XTEN technology was developed by Amunix and human growth hormones linked to XTEN, including VRS-317, are exclusively licensed worldwide to Versartis.

Volker Schellenberger, PhD, Amunix President and Chief Executive Officer, said, "It is extremely gratifying to see our XTEN technology succeeding in human clinical trials, with the VRS-317 pediatric GHD study as the most recent example of the utility of our technology. Current therapies for children with GHD require the burden of daily injections. The Versartis Phase 2a data demonstrate that the efficacy and safety of VRS-317, when administered monthly, semi-monthly and weekly in pediatric patients with GHD, are comparable to daily injections of human growth hormone at the highest approved dose on the labels of the current market leading therapies."

Amunix has developed XTEN, a protein-based polymer that mimics the biophysical properties of PEG. XTEN is easily metabolized, thereby eliminating the risk of tissue accumulation. Single or multiple payloads can be conjugated or genetically fused to XTEN which allows the generation of monospecific, bispecific, as well as multivalent biopharmaceuticals.

About Amunix Amunix Operating Inc., a biotechnology company headquartered in Mountain View, CA, has developed a novel half-life extension technology based on XTEN; hydrophilic, unstructured polypeptides which can be recombinantly fused or chemically conjugated to other peptides, proteins and small molecules. Through this proprietary XTEN technology, the company creates and develops novel versions of clinically-proven pharmaceutical products that may offer better efficacy, safety and dosing frequency by extension of the half-life. One XTEN product, Exenatide-XTEN (VRS-859), has completed a Phase I study through Amunix partner Diartis. Amunix partner Versartis recently completed a Phase 2a clinical trial evaluating weekly, semi-monthly and monthly dosing regimens of hGH-XTEN (VRS-317) in children with growth hormone deficiency. In addition, through its partnership with Biogen Idec, Amunix is developing Factor VIII and is working with Janssen Biotech, Inc. and its affiliates to apply the XTEN half-life extension technology with protein and/or peptide therapeutics selected by Janssen. Amunix has several other undisclosed partners in various therapeutic areas. Founded in 2006, Amunix is a profitable, independent biotechnology company with no external investors. Amunix is actively seeking partnerships for application of its XTEN technology for half-life extension or tumor drug delivery. For additional information about the company, please visit www.amunix.com .

Amunix Media Contact: Debra Catz Bannister Email Contact 530 676-7373

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 53

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
LASIK Cost Math Deserves a Careful Second Look Today

Updated Category News Views 66

Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...

Continue Reading
Stand Takes Colorado Bet on Wildfire-Smart Coverage

Updated Category News Views 90

Colorado’s insurance mess has finally attracted a company willing to price the driveway, the vents, and the tree line instead of shrugging at an entire ZIP code. Stand has launched homeowners coverage across the state, including mountain communities where wildfire exposure has made insurance both costly and scarce. This is not a small problem dressed up with a shiny...

Continue Reading
Medical School Rejections Carry a Steep Price Tag Too

Updated Category News Views 81

A rejection letter can turn into a remarkably expensive piece of paper. BeMo Academic Consulting's new Medical School Admissions Trends Report argues that the damage from missing medical-school admission goes far beyond bruised confidence: applicants can spend thousands chasing another cycle, lose time entering practice, and, if they never get in, forgo what the report...

Continue Reading
AI Echo Study Sharpens a Difficult HFpEF Diagnosis

Updated Category News Views 71

A single echo clip may be doing more useful work than plenty of flashy healthcare AI demos. The November 2026 Journal of Cardiac Failure focus issue puts a hard number on that possibility: pairing an AI read of a routine echocardiogram clip with the H?FPEF clinical score identified 78% of patients with hemodynamically confirmed HFpEF, versus 48% with the score alone. That...

Continue Reading
Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 124

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
AMPERA Joins Berto to Power Future Energy Innovations

Updated Category News Views 58

The Power Play You Didn't See Coming AMPERA and Berto just made a move that could stir up some serious waves in the energy sector. They've inked a business combination deal set to push advanced energy technology to the forefront. With AMPERA's valuation clocking in at roughly $900 million, this partnership aims to bring cutting-edge power solutions from concept to market....

Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector

Updated Category News Views 67

Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 20

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 146

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading

Top 5 Most Recently Viewed Articles

Estimating the Growth of $100 in Webster Financial Shares

Updated Category News Views 237

Understanding Webster Financial's Long-Term Growth Webster Financial, trading under the symbol WBS, has demonstrated a remarkable performance in the stock market over the past five years. The investment landscape can be unpredictable, but looking at WBS, we can observe that it has outperformed the market by an average of 3.91% annually, yielding a total annual return of...

Continue Reading
Grocery Outlet Shareholders Can Pursue Securities Fraud Claims

Updated Category News Views 129

Grocery Outlet Shareholders Can Pursue Securities Fraud Claims Investors have the chance to reclaim their losses after allegations of securities fraud at Grocery Outlet Holding Corp. (NASDAQ: GO). It’s crucial for all purchasers of Grocery Outlet securities who were active during the defined Class Period to understand their rights. Understanding the Class Period The...

Continue Reading
Core Bank Expands Services with New Banking Center Soon

Updated Category News Views 135

Core Bank Relocation to a New Overland Park Facility Core Bank is thrilled to announce its move to a new location for its Overland Park Banking Center. This relocation marks a significant milestone for the bank, allowing it to better serve the growing needs of the community. The modern banking space, set to open soon, is designed with improved accessibility and enhanced...

Continue Reading
Exploring Netflix's Recent Options Activity and Insights

Updated Category News Views 189

Netflix's Recent Options Trading Trends Financial giants have expressed a notable bullish sentiment toward Netflix. Analyzing the recent options trades for Netflix (NASDAQ: NFLX) reveals that 65 unusual trades have taken place, sparking considerable interest among investors. Traders' Sentiments and Volume Analysis Diving into the details, about 56% of traders exhibited...

Continue Reading
Simply Good Foods Faces Securities Fraud Lawsuit Turmoil

Updated Category News Views 53

Simply Good Foods: Murky Waters  Well, here we go again with yet another corporate mess. Simply Good Foods Company’s staring down a securities class action lawsuit over not-so-savory business moves that have knocked their stock into the gutter. The beef? Failing to spill the beans on troubles brewing from an acquisition that's gone south. Now, they’re facing a...

Continue Reading